|
|
CASP16 in numbers
|
|
Number of groups registered | 209
|
|
including: expert groups | 161
|
|
prediction servers | 48
|
| |
|
Number of protein tertiary structure prediction targets released | 156
|
| (including: | |
|
Phase 0 subunits of multimers targets | 35
|
|
Phase 1 targets | 76
|
|
Phase 2 subunits of multimers targets) | 45
|
|
Number of protein multimeric targets released | 108
|
|
(including Phase 0 /Phase 1 /Phase 2 targets) | (30/43/35)
|
|
Number of RNA targets released (monomers and multimers) | 52
|
|
Number of multimeric RNA targets released | 20
|
|
(including Phase 0 /Phase 1 targets) | (9/11)
|
|
Number of hybrid (Protein/RNA/DNA) targets released | 22
|
|
(including Phase 0 /Phase 1 targets) | (4/18)
|
|
Number of incidental ligand targets released | 8
|
|
Number of pharma pose ligand targets released | 233
|
|
Number of pharma affinity ligand targets released | 140
|
|
Number of pharma affinity ligand targets (stage 2) released | 110
|
|
Number of RNA with water shell ensemble targets released | 1
|
|
Number of protein A ensemble targets (disordered) released | 2
|
| |
|
| Tertiary structure
|
125 / 36 |
9896 |
48191 |
| Assembly (heteromeric) |
85 / 31 |
4026 |
19711 |
| Accuracy estimation |
36 / 22 |
1243 |
3108 |
| RNA |
66 / 16 |
1786 |
8416 |
| Hybrid complexes |
56 / 19 |
561 |
2690 |
| Incidental Ligands |
23 / 1 |
192 |
893 |
| Pharma Ligands (pose) |
34 |
5983 |
27174 |
| Pharma Ligands (affinity) |
31 |
3509 |
15193 |
| Pharma Ligands, stage 2 (affinity) |
27 |
2691 |
2691 |
| RNA with water shell |
25 |
25 |
25 |
| Protein A ensembles (disorder) |
39 |
78 |
78 |
| All (unique): |
200 / 48 |
29987 |
128161 |
|
|
|
|
Protein Structure Prediction Center
Sponsored by the US National Institute of General Medical Sciences (NIH/NIGMS)
Please address any questions or queries to:
© 2007-2024, University of California, Davis
Terms of Use
|
